Grants and Contributions:
Title:
Protecting Frontline Health Care Workers (HCWs) from COVID-19 with lambda interferon Pre-exposure Prophylaxis: An Adaptive Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada (HEROs Trial)
Agreement Number:
947684
Agreement Value:
$1,000,000.00
Agreement Date:
Apr 2, 2020 - Jun 30, 2021
Description:
Randomized study that will test the efficacy of lambda interferon to protect front line health care workers from contracting SARS-CoV-2 corona virus which causes COVID-19 disease.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5G 2C4
Reference Number:
172-2020-2021-Q1-947684
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
119259505
Recipient Type:
Not-for-profit organization or charity
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 61 days.
Amendment Date
Mar 3, 2021
Recipient's Operating Name:
UHN
Recipient's Legal Name:
University Health Network
Federal Riding Name:
University--Rosedale
Federal Riding Number:
35110
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
6221
Amendments: